



18 November 2019

ASX ANNOUNCEMENT

**Appendix 3Y
Change of Director's Interest Notice**

Attached is an Appendix 3Y – Change of Director's Interest Notice in respect of changes in the relevant interests in securities held by Richard Carreon, Managing Director & CEO.

Between 12 November 2019 and 14 November 2019, Mr Carreon acquired a total of 486,585 Ordinary Shares.

352,501 Ordinary Shares were acquired through the vesting of Performance Rights. The Performance Rights were granted in November 2016 as part of the 2017 financial year Long Term Incentive Plan. The shares were issued net of performance conditions, as detailed out in the Remuneration Report of the FY19 Annual Report.

134,084 Ordinary Shares were acquired in lieu of base remuneration for the quarter ended 30 September 2019 as part of the Executive Share Plan. The shares were issued net of applicable taxes that were required to be withheld by ImpediMed under the plan rules.

Following this acquisition, Mr Carreon now holds 1,495,176 Ordinary Shares. In addition, Mr Carreon holds 15,648,484 Options and 3,224,871 Performance Rights, which are subject to various time-based and performance conditions.

**Leanne Ralph
Company Secretary**

Media Contact:

Kyahn Williamson, WE Buchan

T: +61 3 9866 4722

E: kwilliamson@buchanwe.com.au

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical software technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscopy (BIS).

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure and lymphoedema, sold in select markets globally.

For more information, visit www.impedimed.com.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity: ImpediMed Limited	
ABN:	089 705 144

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Richard Carreon
Date of last notice	18 July 2019

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	12, 13 and 14 November 2019
No. of securities held prior to change	1,008,591 Ordinary Shares 13,655,872 Options 1,732,000 Performance Shares
Class	1. Ordinary Shares 2. Options 3. Performance Rights
Number acquired	1. 486,585 Ordinary Shares 2. 1,992,612 Options 3. 1,962,871 Performance Rights

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Number disposed	470,000 Performance Rights
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	1a. \$0.15 per share 1b. Nil 2. Nil 3. Nil
No. of securities held after change	1,495,176 Ordinary Shares 15,648,484 Options 3,224,871 Performance Shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	1a. Vesting of Performance Rights, 352,501 Shares issued 1b. Issue of 134,084 Shares in lieu of base remuneration for quarter ended 30 September 2019 2. Grant of 1,992,612 Options 3a. Grant of 1,962,871 Performance Rights 3b. Lapse of 470,000 Performance Rights

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

+ See chapter 19 for defined terms.

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

Date of Notice: 18 November 2019

⁺ See chapter 19 for defined terms.